Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.
about
Current Trends of Renal Impairment in Multiple MyelomaInternational Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationA phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response.Bortezomib in patients with renal impairment.Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone.Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma.Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myelomaLenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.Case report on renal failure reversal in lambda chain multiple myeloma with bortezomib and dexamethasone.Bortezomib in multiple myeloma: systematic review and clinical considerations.Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial.Late recurrence of light chain deposition disease after kidney transplantation treated with bortezomib: a case reportProteasome inhibition and its therapeutic potential in multiple myelomaArsenic Trioxide Combined with VCMP or VAD Chemotherapy in Patients with Refractory or Relapsed Multiple Myeloma in a Single Institution of ChinaProteasome inhibitors in the treatment of multiple myelomaInternational Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients.Bortezomib-based treatment for multiple myeloma patients with renal impairment: A systematic review and meta-analysis of observational studies.Successful treatment with bortezomib and dexamethasone for proliferative glomerulonephritis with monoclonal IgG deposits in multiple myeloma: a case report.Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group StudyLower expression of activating transcription factors 3 and 4 correlates with shorter progression-free survival in multiple myeloma patients receiving bortezomib plus dexamethasone therapy.Caffeic Acid Phenylethyl Ester and MG-132 Have Apoptotic and Antiproliferative Effects on Leukemic Cells But Not on Normal Mononuclear Cells.Current multiple myeloma treatment strategies with novel agents: a European perspectiveKidney disease associated with plasma cell dyscrasiasThe Belgian 2010 consensus recommendations for the treatment of multiple myeloma.Renal failure in multiple myeloma: a medical emergency.Guidelines for the diagnosis and management of multiple myeloma 2011.A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence?Bortezomib for previously untreated multiple myeloma.Management of myeloma-associated renal dysfunction in the era of novel therapies.Novel approaches for reducing free light chains in patients with myeloma kidney.Current treatments for renal failure due to multiple myeloma.Kidney disease and multiple myeloma.Bortezomib-induced peripheral neurotoxicity: an update.Treatment of Newly Diagnosed Elderly Multiple Myeloma.Current Review on High-Risk Multiple Myeloma.Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapyTreatment of Relapsed/Refractory Multiple Myeloma.
P2860
Q26740444-84DC3AC7-9109-40DB-BC89-E82533A796E2Q27002668-44B9D391-7DBF-4A7F-A7A1-8DE9752614CCQ33392245-F6CE8680-C306-4CD8-8921-7F97DC0B8A29Q33396250-A1B31459-FCC6-43BA-A224-890C3C650770Q33398587-317FA2F2-9D3E-43AF-BF37-AB1A203D0FC2Q33400871-49FB902F-7CE1-4DE9-892B-84F5289D32D1Q33404570-BC923D34-A782-47CE-9CF8-CF9C32D7A808Q33408056-1A7FEF7A-5BE8-4714-AB18-DD15AC2871AEQ33418712-1E6AF9BF-D3FB-4011-831F-061D746BAC15Q33558161-DD5D214D-99D2-426B-9147-0CD862FF8AEEQ33874209-6237EFCA-04E0-4535-A9BE-5DB42D668F78Q33982728-74D73EF5-5565-41F6-BF42-9ED8E54696E6Q34063353-53626FC2-462B-4705-818C-C5F01D043EC3Q34228650-E75695C0-5BB3-40B7-8050-4786AEBDBF23Q34343036-C7BAE80B-1A55-43AF-98D5-6F64D5F53FE8Q34569038-BE79A392-CE9C-4F7C-9750-F9434F1B31E0Q34611676-69A5F6C7-3BEA-472E-90E7-0CDDA86ED5B8Q35802414-1CA81773-D5FF-45BD-878B-A2B118026F37Q35893993-C7EBE304-1009-44DF-AC50-4A114CCC9160Q36196981-392263E1-3A92-4633-886B-7DFC5EC5E3C3Q36338914-DCC63038-B578-41E4-A87F-D2BA26E31D1FQ36349396-AEC03E2C-B6D6-4CDA-8C9B-F790A49817A6Q36526514-78B555D0-4F99-40B5-9396-50A589B01FAFQ37109468-91992D66-7D81-48D2-A6DB-FD94710CD152Q37677935-C1B7C882-5C5E-4009-BF03-FE1C76A26932Q37750106-9DC8F91B-FBAA-4CE5-8EEF-FF32F79FFBBBQ37800884-6F7FAA42-DEC5-4CD4-89ED-6156A1AC3976Q37845643-8189C6EC-81B1-4CB0-99C3-611E6B154EB4Q37875193-2FF420A3-6E5D-4EF9-A343-0691933AD169Q37903590-6B9F8481-E2BB-48C9-B8D6-0522A5C25596Q37908155-AF544BA9-9DB5-4C29-A47B-A0E9EEB238EAQ37978343-DB7446F0-D2B2-4D4C-AAFF-B813687B9EBFQ37986358-8AC9049F-E265-4097-9BAD-7783725E835FQ38109235-5240E225-A95B-4B5B-A96D-0E9EED6C64B5Q38122674-9FC33A39-9E98-4F07-82C0-B7B251AD0A8DQ38234733-F868D5A9-DAF7-49B9-BD09-E7AED4ABB4C9Q38815405-3DA2DFC5-1221-4626-BCB8-282F79E10454Q38895167-1933D6F7-D2A9-44F9-A864-9D0AD74C4767Q38949770-04B17224-9740-4E99-A3F8-667F5434F611Q38970597-3D1DFE42-FDF3-438B-A015-2F974D21C010
P2860
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Efficacy and safety of bortezo ...... s from the APEX phase 3 study.
@en
Efficacy and safety of bortezo ...... s from the APEX phase 3 study.
@nl
type
label
Efficacy and safety of bortezo ...... s from the APEX phase 3 study.
@en
Efficacy and safety of bortezo ...... s from the APEX phase 3 study.
@nl
prefLabel
Efficacy and safety of bortezo ...... s from the APEX phase 3 study.
@en
Efficacy and safety of bortezo ...... s from the APEX phase 3 study.
@nl
P2093
P2860
P356
P1433
P1476
Efficacy and safety of bortezo ...... s from the APEX phase 3 study.
@en
P2093
D Ben-Yehuda
D-L Esseltine
E A Stadtmauer
H Goldschmidt
J D Cavenagh
J F San-Miguel
P2860
P2888
P304
P356
10.1038/SJ.LEU.2405087
P577
2008-01-17T00:00:00Z